drug_type
RELEVANT_DRUG
intervention_type
Cell therapy (autologous CAR T cells)
drug_description
Patient-derived T cells genetically engineered to express a chimeric antigen receptor that specifically recognizes Claudin18.2 (CLDN18.2), activating and expanding T cells to mediate targeted cytotoxicity against CLDN18.2-positive tumor cells; administered as up to three infusions.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting Claudin18.2 (CLDN18.2). Antigen engagement triggers CAR signaling, activating and expanding the T cells to mediate targeted cytotoxicity and cytokine release, leading to selective killing of CLDN18.2-positive tumor cells.
drug_name
CT041 autologous CAR T-cell injection
nct_id_drug_ref
NCT05911217